menu
    • menu
    [{"orgOrder":0,"company":"Sirnaomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"STP122G","moa":"Factor XI expression","graph1":"Hematology","graph2":"IND Enabling","graph3":"Sirnaomics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"","sponsorNew":"Sirnaomics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Sirnaomics \/ Not Applicable"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"STP122G","moa":"Factor XI expression","graph1":"Hematology","graph2":"IND Enabling","graph3":"Sirnaomics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sirnaomics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Sirnaomics \/ Not Applicable"},{"orgOrder":0,"company":"Coagulant Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"CT-001","moa":"","graph1":"Hematology","graph2":"IND Enabling","graph3":"Coagulant Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Coagulant Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Coagulant Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Mabwell","sponsor":"Disc medicine","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"CHINA","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"MWTX-001","moa":"","graph1":"Hematology","graph2":"IND Enabling","graph3":"Mabwell","amount2":0.40999999999999998,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Hematology","amount2New":0.40999999999999998,"dosageForm":"","sponsorNew":"Mabwell \/ DISC MEDICINE","highestDevelopmentStatusID":"5","companyTruncated":"Mabwell \/ DISC MEDICINE"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Regen BioPharma

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Regen BioPharma

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Stem Cell-derived Therapy

                            Therapeutic Area : Hematology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Regen BioPharma, Inc. Expands Vision for Phase 1 Clinical Trial of HemaXellerate™

                            Details : HemaXellerate is an innovative stem cell-derived therapy, designed to stimulate bone marrow regeneration, it has already received FDA clearance for treating aplastic anemia.

                            Brand Name : HemaXellerate

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            November 19, 2024

                            Lead Product(s) : Stem Cell-derived Therapy

                            Therapeutic Area : Hematology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Ainos

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Ainos

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Interferon Alfa

                            Therapeutic Area : Hematology

                            Study Phase : IND Enabling

                            Sponsor : Lind Partners

                            Deal Size : $1.7 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Ainos Announces $1.75 Million Follow-On Funding

                            Details : Veldona (interferon alfa) is progressing towards IND applications for human drug candidates and co-development of VOC sensing tech using AI Nose.

                            Brand Name : Veldona

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            January 24, 2024

                            Lead Product(s) : Interferon Alfa

                            Therapeutic Area : Hematology

                            Highest Development Status : IND Enabling

                            Sponsor : Lind Partners

                            Deal Size : $1.7 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Mabwell

                            China arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Mabwell

                            China arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MWTX-001

                            Therapeutic Area : Hematology

                            Study Phase : IND Enabling

                            Sponsor : Disc medicine

                            Deal Size : $412.5 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Mabwell Announces Exclusive Licensing Agreement with Disc Medicine, Inc. for Innovative Drug Candidates of Hem...

                            Details : Under the terms of the agreement, Disc will obtain exclusive rights to develop and commercialize 9MW3011. MWTx 01 is a recombinant monoclonal antibody targeting a key regulator in the iron homeostasis pathway, developed to treat iron overload disorders.

                            Brand Name : MWTX-001

                            Molecule Type : Large molecule

                            Upfront Cash : $10.0 million

                            January 20, 2023

                            Lead Product(s) : MWTX-001

                            Therapeutic Area : Hematology

                            Highest Development Status : IND Enabling

                            Sponsor : Disc medicine

                            Deal Size : $412.5 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Coagulant Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Coagulant Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CT-001

                            Therapeutic Area : Hematology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Coagulant Therapeutics Announces Upcoming Oral and Poster Presentations at the 2022 American Society of Hemato...

                            Details : CT-001 is an engineered version of FVIIa that is designed to address the limitations of the recombinant FVIIa, approved for use in Hemophilia A and B patients with inhibitors, congenital FVII deficiency.

                            Brand Name : CT-001

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            November 16, 2022

                            Lead Product(s) : CT-001

                            Therapeutic Area : Hematology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Coagulant Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Coagulant Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CT-001

                            Therapeutic Area : Hematology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Coagulant Therapeutics Presents Data for Severe Postpartum Hemorrhage Clinical Candidate, CT-001, at Internati...

                            Details : CT-001 is an engineered version of clotting factor FVIIa designed to address safety and efficacy limitations of recombinant FVIIa is approved for use in Hemophilia A and B patients with inhibitors.

                            Brand Name : CT-001

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            July 12, 2022

                            Lead Product(s) : CT-001

                            Therapeutic Area : Hematology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Sirnaomics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Sirnaomics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : STP122G

                            Therapeutic Area : Hematology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Sirnaomics to Present the Latest Developments of Dual-Targeted RNAi Therapeutics Based on its Proprietary GalA...

                            Details : STP122G is in early-stage development as an anticoagulant in settings where antithrombotic therapeutics are needed such as stroke patients and orthopedic surgery patients. STP122G targets Factor XI, a plasma glycoprotein that is primarily synthesized in ...

                            Brand Name : STP122G

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            June 21, 2022

                            Lead Product(s) : STP122G

                            Therapeutic Area : Hematology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Sirnaomics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Sirnaomics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : STP122G

                            Therapeutic Area : Hematology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Sirnaomics to Present Latest Developments on its GalNAc-Based Liver-Targeting Platforms and GalAhead™ Progra...

                            Details : STP122G comprises RNAi triggers targeting Factor XI. Factor XI is a plasma glycoprotein that is primarily synthesized in the liver and is part of the coagulation cascade, playing a role in clot stabilization and expansion.

                            Brand Name : STP122G

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            May 11, 2022

                            Lead Product(s) : STP122G

                            Therapeutic Area : Hematology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Omeros

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Omeros

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OMS906

                            Therapeutic Area : Hematology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Omeros’ Investigational New Drug Application for OMS906 Cleared by FDA

                            Details : OMS906 is the company’s lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-3 (MASP-3), the key activator of the complement system’s alternative pathway.

                            Brand Name : OMS906

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            August 31, 2020

                            Lead Product(s) : OMS906

                            Therapeutic Area : Hematology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth